Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula

Summary

This study aims to explore the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients and the compositional and functional changes in the gut microbiome of breast cancer patients undergoing chemotherapy and treatment with BLHK03.

Eligibility

Inclusion Criteria:

* Females aged between 18 and 60 years who are newly diagnosed with stage I, II or III breast cancer
* Planned chemotherapy including an anthracycline or taxane to be completed within 6 months
* Mentally capable to participate in the study and provide informed consent

Exclusion Criteria:

* Pre-existing female-pattern baldness resembling picture I-3 or higher on the Savin scale at baseline
* History of hair transplantation, psoriasis or severe scalp infection
* Undergoing or plan to receive scalp cooling
* Plan for immunotherapy
* Known pregnancy or lactating
* Severe cardiac, hepatic, renal, pulmonary and haematic lesions or other life-threatening conditions
* Use of antibiotics, probiotics or prebiotics one month prior to enrolment
* No other alternative or complementary treatment for the cancer condition that may affect the gut microbiome analysis
* History of allergy to probiotics or lactose
* History of chemotherapy for other conditions

Conditions3

Browse More Trials